Cannon Global Investment Management, LLC
Position in TERN — Terns Pharmaceuticals, Inc.
CIK 1844427
DAVIE, FL
Position in TERN
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$474,480
New position
Shares Held
9,000
first reported quarter
Ownership
0.008%
of shares outstanding
% of Portfolio
1.20%
of 13F equity value
Holder Rank
#220
of 316 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in TERN
reported options exposure · as of Mar 31, 2026CallValue
$1,318,000
CallShares
25,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cannon Global Investment Management, LLC holds $6,313,618 across 19 Biotechnology names. TERN ranks #4 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
8,500 | $826,625 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,400 | $794,088 | |
| 3 | ABVX |
Abivax S.A.
|
6,000 | $668,100 | |
| 4 | TERN |
Terns Pharmaceuticals, Inc.
This page
|
9,000 | $474,480 | |
| 5 | CTMX |
CytomX Therapeutics, Inc.
|
96,100 | $451,670 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
5,100 | $427,992 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
800 | $418,776 | |
| 8 | RNA |
Atrium Therapeutics, Inc.
|
25,087 | $335,413 |
All Filings in TERN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $474,480 | 9,000 | Shares | Sole | 2026-04-21 | |
| 2026-03-31 | $1,318,000 | 25,000 | Call | Sole | 2026-04-21 | |
| No filing history on record for this holder in this stock. | ||||||